B. longum CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice

ABSTRACTThe gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of Bifidobacterium longum NBM7–1 (CKD1) with anti-diabetic medicines, LobeglitazoneⓇ (LO), SitagliptinⓇ (...

Descripció completa

Dades bibliogràfiques

Autors principals:	Won Jun Kim, Bum Ju Kil, Chaewon Lee, Tae Young Kim, Goeun Han, Yukyung Choi, Kyunghwan Kim, Chang Hun Shin, Seung-Young Park, Heebal Kim, Myunghoo Kim, Chul Sung Huh
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2024-12-01
Col·lecció:	Gut Microbes
Matèries:	Bifidobacterium longum CKD1 anti-diabetic medicines IL-22 signaling insulin resistance hepatic steatosis
Accés en línia:	https://www.tandfonline.com/doi/10.1080/19490976.2024.2319889
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!